WILLIAM E. ROTE - 24 Dec 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Research Officer
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
24 Dec 2025
Net transactions value
-$1,169,580
Form type
4
Filing time
29 Dec 2025, 21:05:37 UTC
Previous filing
05 May 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ROTE WILLIAM E. Chief Research Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 29 Dec 2025 0001698262

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $1,236,600 +60,000 +59% $20.61 161,443 24 Dec 2025 Direct F1
transaction TVTX Common Stock Sale $2,406,180 -60,000 -37% $40.10 101,443 24 Dec 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -60,000 -100% $0.000000 0 24 Dec 2025 Common Stock 60,000 $20.61 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 607 shares of Common Stock that were acquired by the Reporting Person on May 30, 2025, and 595 shares of Common Stock that were acquired by the Reporting Person on November 28, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.
F2 This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on February 13, 2017, with an expiration date of February 13, 2027.
F3 The weighted average sale price for the transaction reported was $40.103, and the range of prices were between $38.00 and $42.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4 The stock option is fully vested and exercisable.